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α-cell glucokinase suppresses glucose-regulated
glucagon secretion
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Ioannis Spiliotis2, Xavier Berney1, David Tarussio1, Patrik Rorsman2 & Bernard Thorens1
Glucagon secretion by pancreatic α-cells is triggered by hypoglycemia and suppressed by
high glucose levels; impaired suppression of glucagon secretion is a hallmark of both type 1
and type 2 diabetes. Here, we show that α-cell glucokinase (Gck) plays a role in the control of
glucagon secretion. Using mice with α-cell-speciﬁc inactivation of Gck (αGckKO mice), we
ﬁnd that glucokinase is required for the glucose-dependent increase in intracellular ATP/ADP
ratio and the closure of KATP channels in α-cells and the suppression of glucagon secretion at
euglycemic and hyperglycemic levels. αGckKO mice display hyperglucagonemia in the fed
state, which is associated with increased hepatic gluconeogenic gene expression and hepatic
glucose output capacity. In adult mice, fed hyperglucagonemia is further increased and
glucose intolerance develops. Thus, glucokinase governs an α-cell metabolic pathway that
suppresses secretion at or above normoglycemic levels; abnormal suppression of glucagon
secretion deregulates hepatic glucose metabolism and, over time, induces a pre-diabetic
phenotype.
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G lucagon secretion by pancreatic α-cells is rapidlyincreased when the blood glucose concentration fallsbelow the normoglycemic level to increase hepatic glucose
production, and is suppressed by hyperglycemia1,2. The
mechanisms controlling hypoglycemia-induced glucagon secre-
tion remain debated, and both intrinsic and paracrine mechan-
isms have been postulated (reviewed in refs. 3,4). There is
evidence that hypoglycemia triggers glucagon secretion via a fall
in the cytoplasmic ATP/ADP ratio, leading to moderate KATP
channel activity and increased activity of P/Q type Ca++ chan-
nels3. The resulting increase in intracellular Ca2+ leads to gluca-
gon secretory granules exocytosis. Extrinsic factors also play an
important role in triggering glucagon secretion, in particular, the
signals from the sympathetic and parasympathetic branches of
the autonomic nervous system4,5, which are activated by
hypoglycemia-sensing neurons present in the extrapancreatic
sites, such as the hepatoportal vein area6,7 and the central nervous
system5,8,9. On the other hand, suppression of glucagon secretion
by hyperglycemia relies on paracrine regulation, including
insulin-induced inhibition and/or somatostatin-induced inhibi-
tion of α-cells10.
In pancreatic β-cells, the dose response of glucose-stimulated
insulin secretion is controlled by the activity of glucokinase
(Gck), which has relatively high KM for glucose (8 mM)11.
Mutations that increase the KM for glucose of this enzyme shifts
the dose response of GSIS to the right, causing Maturity Onset
Diabetes of the Young 2 (MODY2)12. Glucokinase is also
expressed in α-cells13, but its role in the control of glucagon
secretion is not known. Studies of MODY2 patients during
stepped hyperinsulinemic/hypoglycemic clamps showed that
glucagon secretion was stimulated at higher glucose concentra-
tion than in control individuals, but whether this was due to a
direct effect in the α-cells or secondary to altered glucose-sensing
by the central nervous system and altered autonomic nervous
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Fig. 1 Alpha-cell Gck inactivation and the suppression of glucagon secretion. a Representative immunoﬂuorescence (out of n= 3 replicates) of the co-
localization of glucagon (green) and tdtomato (red) in a pancreatic section from αGckKO-Rosa26tdtomato mice. Scale bar: 100 µm. b PCR analysis of
recombination of the Gckﬂox allele in the indicated tissues of Ctrl and αGckKO mice. c Pancreas' weight normalized to BW. See also Supplementary Fig. 1.
d Islet surface expressed as percentage of total pancreatic surface. e α-cell mass. f β-cell mass. Values in b–h were extracted from the analysis of three
pancreata for each genotype. g Glucagon and h Insulin secretion from isolated islets in the presence of the indicated glucose (G) concentrations and of
tolbutamide. g, h Data represent the average of three independent experiments, each performed in duplicates. ***p< 0.001 vs. Ctrl 1G; **p< 0.01 vs.
αGckKO 1G + Tolb. #p< 0.01 vs. Ctrl 6 G. §p< 0.001 vs. Ctrl 20G.∞p< 0.05 vs. Ctrl 1G + Tolb. One-way ANOVA for intra-group analysis and Student’s t-
test for comparison between genotypes. i ATP/ADP ratio measurements in α-cells of Ctrl and αGckKO islets exposed to glucose and methyl-succinate
(msucc). n= 116 for Ctrl and n= 86 for αGckKO α-cells. See also Supplementary Figs. 2 and 3. Data are represented as mean± s.e.m.
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activity remains unclear14. Here we explore the role of Gck in the
pancreatic α-cell by generating α-cell-speciﬁc Gck knockout
mice. Our data illustrate that Gck is critical to glucose sensing in
the α-cell and underscore the signiﬁcance of intrinsic (exerted
within the α-cell itself) as opposed to paracrine/systemic
regulation.
Results
Characterization of αGckKO islets. To generate mice with
inactivation of the Gck gene in α-cells (αGckKO mice), we crossed
Gcklox/lox mice9 with preproglucagon-Cre (Gcg-Cre) mice15. These
mice were further crossed with Rosa26-tdtomato mice and ~70%
of the glucagon-positive cells also expressed tdtomato (Fig. 1a),
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indicating that a large majority of α-cells express the Cre
recombinase. The recombined Gck allele was detected in islets of
αGckKO mice, but not in their liver, brainstem, and ileum tissues
that also express the preproglucagon gene, but not the Cre
recombinase in the Gcg-Cre mice utilized (Fig. 1b). Pancreas
mass, islet surface area, α-cell mass and β-cell mass (Fig. 1c–f), as
well as pancreatic insulin and glucagon contents (Supplementary
Fig. 1) were the same in Ctrl and αGckKO mice.
The impact of α-cell Gck gene inactivation on glucagon
secretion was then examined by static incubations. At 1 mM
glucose, glucagon secretion by islets from 18-week-old Ctrl and
αGckKO mice was comparable (Fig. 1g, black bars). When
incubated with 6 and 20 mM glucose, glucagon release by Ctrl
islets was decreased by ~50%, but not in αGckKO islets (Fig. 1g).
Tolbutamide, which closes the KATP channel independently of
glucose metabolism and changes in the ATP/ADP ratio, produced
a comparable inhibition of glucagon secretion in both types of
islets when applied at 1 mM glucose (Fig. 1g, white bars). Insulin
secretion by Ctrl and αGckKO islets was similarly stimulated by
increases in glucose concentrations (Fig. 1h). Thus, although Gck
is not required for the high rate of glucagon secretion at 1 mM
glucose, it is critical to the suppression produced by elevated
glucose.
Suppressed glucose-induced ATP production in αGckKO α-
cells. To assess whether Gck inactivation prevented ATP pro-
duction in the presence of elevated extracellular glucose con-
centrations, we measured the intracellular ATP/ADP ratio in Ctrl
and αGckKO-Rosa26tdtomato α-cells transduced with a recom-
binant adenovirus to express the Perceval reporter protein16.
Perceval ﬂuorescence in tdtomato-expressing α-cells was mea-
sured by confocal microscopy in the presence of different glucose
concentrations (Fig. 1i). In control α-cells, the ATP/ADP ratio
increased in the presence of 3 and 10 mM glucose, an effect that
was fully reversible upon return to 1 mM glucose. The glucose-
induced increase in cytoplasmic ATP/ADP-ratio was absent in α-
cells from αGckKO mice. However, application of methyl-
succinate (msucc), a cell-permeable substrate of the tri-
carboxylic cycle, produced similar increment in the ATP/ADP
ratio in Ctrl and αGckKO α-cells. In a separate experiment, we
measured the ATP/ADP ratio at 1, 3, and 6 mM glucose. Over
this narrower range of glucose concentrations, we observed a
clear increase in the ATP/ADP ratio already at 3 mM glucose in
Ctrl α-cells, but not in α-cells from αGckKO mouse islets (Sup-
plementary Fig. 2). Glucose-induced changes in the ATP/ADP
ratio in β-cells from αGckKO islets were identical to those in
control islets (Supplementary Fig. 3).
Electrophysiology in αGckKO islets. We next performed elec-
trophysiological analysis of α-cells in Ctrl and αGckKO islets. At
1 mM glucose, α-cells from Ctrl and αGckKO islets were elec-
trically active and ﬁred overshooting action potentials that peaked
at 8± 4 mV (n = 5) and 11± 3mV (n = 4) for Ctrl and αGckKO
α-cells, respectively (Fig. 2a). In agreement with previous data,
increasing glucose to 6 mM resulted in a small and reversible
membrane depolarization (+6± 2 mV, n = 5) and an ~10mV
reduction of the action potential peak voltage in α-cells from Ctrl
islets. By contrast, increasing glucose neither depolarized nor
reduced the action potential peak voltage in αGckKO α-cells
(Fig. 2a–c). In αGckKO α-cells, glucose, if anything, tended to
hyperpolarize the α-cell and increase action potential height.
These effects may reﬂect somatostatin release from the neigh-
boring δ-cells17.
In Ctrl α-cells, increasing glucose reduced the resting KATP
conductance by 24± 11pA/pF; no such decrease was observed in
αGckKO α-cells (Fig. 2d, e).
We ascertained (using capacitance measurements3) that
depolarization-evoked exocytosis was the same in Ctrl and
αGckKO α-cells: in both cell types, membrane depolarization to 0
mV produced step increases in membrane capacitance (Fig. 2f).
The voltage dependence of exocytosis in α-cells is summarized in
Fig. 2g. Exocytosis was steeply voltage-dependent at membrane
potentials between −20 and + 10 mV.
We performed electrophysiological analysis of glucose-induced
electrical activity in β-cells from adult αGckKO and Ctrl mice.
When exposed to stimulatory concentrations of glucose (10 or 20
mM), β-cells of both genotypes were depolarized and ﬁred bursts
of action potentials (Supplementary Fig. 4).
Hyperglucagonemia and gluconeogenesis in αGckKO mice.
Eighteen to twenty weeks old female and male Ctrl and αGckKO
mice had similar body weight (Fig. 3a and Supplementary
Fig. 5a), blood glucose levels, and plasma insulin in fed, fasted,
and fasted and 2-hours refed states (Fig. 3a–c for female mice and
Supplementary Fig. 5a–c for male mice). Plasma glucagon levels
were similar in fasted and 2-hours refed mice, but were 30%
higher in the fed condition in female αGckKO mice (Fig. 3d). A
similar trend was also found in αGckKO male mice (Supple-
mentary Fig. 5d). Glucose tolerance determined after intraper-
itoneal (Fig. 3e) or oral (not shown) glucose administration was
normal in female αGckKOmice, as was in vivo glucose-stimulated
insulin secretion (GSIS) (Fig. 3e, f).
To determine whether the hyperglucagonemia observed in fed
female mice was impacting liver glucose metabolism, we ﬁrst
measured phosphorylated cAMP response element–binding
protein (pCREB) and the level of expression of phosphoenolpyr-
uvate carboxykinase (Pepck) and glucose-6-phosphatase (G6Pase)
mRNAs in fed and overnight fasted mice. Analysis of pCREB/
CREB ratio showed that pCREB was two-fold higher in the fed
state in the livers of αGckKO than that in Ctrl mice (Fig. 3g). Both
Pepck and G6Pase mRNAs were expressed at a higher level in the
liver of fed αGckKO mice as compared to Ctrl mice, whereas no
signiﬁcant differences were detected between genotypes in
overnight fasted mice (Fig. 3h,i). The expression levels of Gck
(Fig. 3j) and several fatty acid oxidation genes (Mcad, Pgc-1α,
Cpt-1) and fatty acid synthesis (Fas, Acc) were also measured and
found to be similar in the livers of Ctrl and αGckKO mice
(Supplementary Fig. 6a–e).
Fig. 2 Electrophysiology of αGckKO α-cells. a Examples of α-cells electrical activity in response to the indicated glucose concentration recorded from Ctrl
(top line) and αGckKO islets (bottom line). Right panels: single action potentials recorded at 1G (black) or 6G (red) with expanded time scale. See also
Supplementary Fig. 4. b Summary of Ctrl α-cell action potential peak voltage, anti-peak voltage, and ﬁring frequency in response to 1G and 6G glucose. n= 4;
*p< 0.05; Student’s t-test. c Same as b for αGckKO α-cells. n= 4. d Examples of KATP current measured in α-cells of Ctrl (upper panel) and αGckKO (lower
panel) islets. e Summary of KATP conductance, expressed as delta between 1G and 6G glucose (normalized to cell size; pS/pF), measured at 1G and 6G. n=
6 per genotype. *p< 0.05; Student’s t-test. Data are represented as mean± s.d. f Voltage-dependent exocytosis in α-cells of Ctrl (middle traces) and
αGckKO (bottom traces) islets. Cell exocytosis was monitored as increase in cell membrane capacitance (ΔCm) induced by membrane depolarizations.
The responses were evoked by depolarizations from −70mV to the indicated voltages (top schematic traces: red −30mV, blue 0mV + 30mV). g
Relationship of the α-cell exocytosis (ΔCm) with depolarizations from −70mV to different voltages (V). Open circles Ctrl (n= 10), black ﬁlled circles
αGckKO (n= 6). Data are represented as mean± s.e.m.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-03034-0
4 NATURE COMMUNICATIONS |  (2018) 9:546 |DOI: 10.1038/s41467-018-03034-0 |www.nature.com/naturecommunications
To assess whether the higher expression of gluconeogenic
genes in fed αGckKO mice was associated with increased
gluconeogenic activity, we performed pyruvate tolerance tests.
Fig. 3k shows that pyruvate administration led to signiﬁcantly
higher blood glucose levels in αGckKO mice as compared to Ctrl
mice (p< 0.01). As enhanced hepatic glucose output in αGckKO
mice was not associated with fed hyperglycemia (see Fig. 3b), we
hypothesized that increased glucose disposal could maintain
normal glycemic control. We thus performed in vivo radioactive
2-deoxy-glucose (14C-2DG) uptake assays to monitor glucose
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Fig. 3 Increased hepatic glucose production in αGckKO mice. a Body weight, b Blood glucose, c Plasma insulin, and d Plasma glucagon. a–d 20 week-old
female mice. n= 19 Ctrl and n= 27 αGckKO mice; **p< 0.01. Student’s t-test. See also Supplementary Fig. 5. e Intra-peritoneal glucose tolerance test. n=
13 mice for each genotype. f Plasma insulin at the indicated times before and after i.p. glucose injection. n= 13 mice for each genotype. g CREB and
phosphorylated CREB in fed and fasted Ctrl and αGckKO mouse livers. See also Supplementary Fig. 8. h Pepck, i G6Pase and j Gck mRNA levels in the livers
from fed and fasted Ctrl and αGckKO mice. h–j n= 4–5 per genotype; *p< 0.05, **p< 0.01, ***p< 0.001, #p< 0.05 vs. Ctrl fed state; Student’s t-test. See
also Supplementary Fig. 6 and Supplementary Table 1. k Pyruvate tolerance test. n= 11 mice per genotype; **p< 0.01 (Two-way ANOVA). l 14C-2DG
uptake in the indicated tissues of Ctrl and αGckKO mice. n= 9 Ctrl and n= 10 αGckKO mice. *p< 0.05; Student’s t-test. Data are represented as
mean± s.e.m.
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uptake in various tissues. 14C-2DG uptake was higher in skeletal
muscle (gastrocnemius and soleus) of αGckKO mice as compared
to Ctrl mice (Fig. 3i). No differences in glucose uptake were found
in the heart, white and brown adipose tissues. Thus, fed
hyperglucagonemia increased hepatic gluconeogenic gene expres-
sion and activity. Normal glycemic control was, however,
preserved because of increased glucose uptake in skeletal muscles,
which was, however, not associated with increased insulin
sensitivity as measured by insulin tolerance test (Supplementary
Fig. 6f).
Hyperglucagonemia and prediabetes in adult αGckKOmice. To
evaluate whether the observed deregulations of glucagon secretion
and liver metabolism can induce long-term impairment in glu-
cose homeostasis, we studied 36-week-old Ctrl and αGckKOmice.
No signiﬁcant differences in body weight, fed blood glucose, and
plasma insulin levels were detected between Ctrl and αGckKO
mice levels (Fig. 4a–c). As was the case in younger mice, adult
αGckKO female mice had a higher fed plasma glucagon level
(+45%) than Ctrl mice (Fig. 4d), and developed mild glucose
intolerance after an overnight fast (Fig. 4e). In in vivo glucose-
stimulated insulin secretion experiments (after a 6-h fast),
αGckKO female mice secreted signiﬁcantly more insulin 30 min
after i.p. glucose injection (Fig. 4g), despite similar blood glucose
levels (Fig. 4f); their glucagonemia was also signiﬁcantly elevated
30ʹ before i.p. glucose injection (Fig. 4h). To assess whether the
increase in insulin secretion was caused by increased β-cell
secretion capacity, we performed insulin secretion experiments
using isolated islets. Fig. 4i shows that insulin secretion was
markedly higher in islets from adult αGckKO mice as compared
to those of adult Ctrl mice, despite identical islet insulin contents
(Fig. 4j). To determine whether this could be due to increased
glucagon secretion from α-cells or to increased processing of
preproglucagon into, and secretion of GLP-1 from α-cells, we
performed insulin secretion experiments in the presence of the
glucagon receptor antagonist L-168,049 and of the GLP-1R
antagonist exendin(9-39). No inhibitory effects on glucose-
stimulated insulin secretion by islets from αGckKO mice could
be observed in these conditions (Supplementary Fig. 7a, b); qRT-
PCR analysis also showed that the level of Pcsk1/3 was not
increased in αGckKO α-cells (Supplementary Fig. 7c).
Discussion
Here, we show that inactivation of Gck in α-cells results in
hyperglucagonemia in the fed state and increased hepatic glucose
production. In adult mice, these initial defects lead to a further
increase in fed hyperglucagonemia and mild glucose intolerance.
This is also associated with increased insulin secretion in response
to glucose stimulation in vivo and in vitro, indicating that, over
time, unsuppressed glucagon secretion induces a compensatory
increase in insulin secretion.
It is now well established that stimulation of glucagon secretion
depends on an α-cell intrinsic hypoglycemia detection system3
and on extrinsic signals, in particular, arising from increased
autonomic nervous activity4,8,18. The dramatic effect of genetic
ablation of Gck in α-cells on the capacity of glucose to suppress
glucagon secretion while leaving glucose-sensing in the non-α-
cells illustrates the importance of intrinsic (i.e., within the α-cell
itself) regulation of glucagon secretion. A current model of the
regulation of the α-cells postulates that an increase in (plasma)
glucose inhibits glucagon secretion via an increase in intracellular
ATP/ADP ratio and closure of ATP-regulated K+ channel, which
results in membrane depolarization and voltage-dependent
inactivation of the voltage-gated Na+ channels involved in
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female mice (n = 9 Ctrl and n = 13 αGckKO mice). **p< 0.01 vs. Ctrl. e I.p. glucose tolerance test. Inset: area under the curve (AUC). *p< 0.05 vs. Ctrl.
Student’s t-test. f Blood glucose, g Plasma insulin, and h Plasma glucagon, at the indicated time before or after i.p. glucose injection. *p< 0.05 vs. relative
Ctrl. i Glucose-stimulated insulin secretion from islets isolated from 36-week-old mice. *p< 0.05 vs. relative Ctrl. Student’s t-test. j Total insulin content
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action potential ﬁring, leading to a diminution of action potential
height and a decreased activation of the P/Q Ca2+ channels that
mediate the Ca2+ entry, triggering glucagon release19. This
mechanism is almost maximally activated at glucose concentra-
tions not associated with any (major) stimulation of insulin and
glucagon secretion18. We acknowledge that other mechanisms for
intrinsic regulation of glucagon secretion have been proposed
(reviewed by Gylfe; see ref. 19), and that the involvement of an
intrinsic regulation does not negate the possibility that the α-cell
is also under paracrine, hormonal, and neuronal control. Clearly,
Gck in α-cells is a necessary component of the glucose-sensing
apparatus. It is interesting that α-cells remain capable of electrical
activity even after genetic ablation of Gck. Clearly, the cyto-
plasmic ATP/ADP ratio remains sufﬁciently high in α-cells at low
glucose and in the absence of activation of Gck to keep the KATP
channels sufﬁciently closed to allow action potential ﬁring. How
this occurs remains unclear, but it is notable that α-cells express
hexokinase 1 (Hk1), a high-afﬁnity hexokinase. It will be inter-
esting to explore the phenotype in mice lacking Hk1.
Circulating glucagon levels were identical in Ctrl and αGckKO
mice in fasted conditions and similarly reduced after a short
period of refeeding. This indicates that suppression of glucagon
secretion in vivo relies on multiple mechanisms in addition to the
Gck-dependent inhibitory effect. A paracrine action of insulin and
somatostatin may play a role in this refed condition. Regardless of
the mechanism(s) involved, it is clear that hyperglucagonemia in
the fed state of αGckKO mice has a signiﬁcant impact on hepatic
glucose metabolism, as revealed by the increases in p-CREB
levels, in Pepck and G6pase expression and in pyruvate-stimulated
gluconeogenesis. In young mice, these defects are not associated
with fed hyperglycemia or glucose intolerance because of the
measured increase in glucose uptake by muscles. This increased
uptake cannot be linked to higher insulin sensitivity as measured
in insulin tolerance tests; it could perhaps be explained by the
recently identiﬁed muscle-speciﬁc glucose sensing mechanism
that increases muscle glucose uptake20. In adult mice, fed
hyperglucagonemia is even more marked than in young mice and
is associated with small glucose intolerance, and an increase in
plasma insulin measured 30min after i.p. glucose injection.
Interestingly, glucose-induced insulin secretion was markedly
higher in islets isolated from αGckKO mice than from Ctrl mice,
despite similar insulin contents. This indicates that glucagon
oversecretion is compensated by an adaptation of the β-cell
insulin secretion capacity, which develops over time since insulin
secretion by islets from young Ctrl and αGckKO mice was
identical. This β-cell adaptation may result from direct α-cell to β-
cell communication, other than through glucagon or GLP-1 sig-
naling, or may be indirect, following changes in hepatic glucose
metabolism that could increase β-cell glucose competence as
described, for instance, in mice with liver-speciﬁc Glut2
inactivation21.
Both type 1 and type 2 diabetes are associated with increased
glucagon secretion and exacerbates the hyperglycemia resulting
from the lack of insulin22,23. Hyperglucagonemia in type 1 dia-
betes may be caused by the total loss of insulin secretion, and of
its inhibitory effect on α-cells. In type 2 diabetes, oral glucose fails
to normally suppress glucagon secretion24, and insulin resistance
of the α-cells may explain part of this defect25. Our present
ﬁndings suggest that defects in Gck expression and/or in the
regulation of its enzymatic activity, which can be controlled by
various intracellular regulators26, may participate in the unrest-
rained secretion of glucagon in diabetes. As mentioned above14,
plasma glucagon levels are suppressed at a higher glycemic levels
in MODY2 patients as compared to control individuals. Our data
suggest that this deregulation can be explained, at least in part, by
reduced Gck activity in α-cells. Finally, our ﬁndings also suggest
that Gck activators, which are being evaluated in the therapy of
diabetic hyperglycemia27, work not only by increasing insulin
secretion and hepatic glucose uptake, but also by reducing glu-
cagon secretion by increasing glycolytic activity and the ATP/
ADP ratio to block KATP channels.
Collectively, our data demonstrate the role of Gck in the
glucose-dependent suppression of glucagon secretion, and iden-
tify a glucose-signaling step in α-cells whose defect can contribute
to disturbances of glucose homeostasis, principally through
deregulation of hepatic glucose metabolism. These deregulations
are accompanied with an adaptation of β-cell secretion capacity,
which may, however, not be sufﬁcient to prevent development of
a prediabetes phenotype. Better characterization of α-cell Gck
activity, its regulation in diabetic conditions, and its response to
speciﬁc endogenous or pharmacological modulators could pro-
vide new ways to control hyperglucagonemia in diabetes.
Methods
Animals. Male and female mice of a C57B6/J background were housed in groups
(from 2 to 5 mice per cage), and maintained at 23 °C on a 12 h light/dark cycle with
ad libitum access to chow diet (Diet 3436; Provimi Kliba AG, Kaiseraugst, Swit-
zerland). Studies were conducted in animals of 18–36 weeks of age, and included
age-matched and sex-matched littermate control mice. For all experiments, the
mice were randomly assigned to experimental groups to ensure an unbiased dis-
tribution of animals. No blinding was used. All animal procedures were performed
at the University of Lausanne and were reviewed and approved by the Veterinary
Ofﬁce of Canton de Vaud. The numbers of animals studied per genotype are
indicated within each experiment.
Generation of αGckKO mice. Gcg-cre mice15 were mated with Gck-ﬂoxed mice9
to generate Gcklox/lox (Ctrl) and Gcg-Cre::Gcklox/lox (αGckKO) mice. For some
experiments, Rosa26tdtomato mice were bred with Gcklox/lox mice to generate Gcg-
Cre;Rosa26-tdtomato;Gck+/+ (Ctrl-Rosa26tdtomato) and Gcg-Cre;Rosa-26tdto-
mato;Gcklox/lox mice (αGckKO-Rosa26tdtomato). To validate proper gene target-
ing, genomic DNA has been extracted from liver, hindbrain, ileum, and pancreatic
islets using a Quick gDNA mini-prep kit (Zymo Research, USA). RT-PCR analysis
was performed using a Biometra T3000 Thermocycler. Recombination efﬁciency
was assessed in αGckKO-Rosa26tdtomato mice. Pancreata from 5-week-old mice
were collected, ﬁxed with 4% paraformaldehyde, and embedded in parafﬁn. Sec-
tions that were 5-μm-thick were stained with guinea pig anti-glucagon (Linco,
diluted 1:500). Recombination efﬁciency was calculated as the percentage of
glucagon-positive cells that also expressed tdtomato.
Histomorphometric analysis. Pancreata were ﬁxed with 4% paraformaldehyde
and embedded in parafﬁn, and 5-μm-thick sections were prepared. For detection of
insulin and glucagon, the sections were heated in a microwave in a citrate buffer
(12 mM, pH 6.0), preincubated in a permeabilization blocking buffer (0.1 M PBS
pH 7.4, 2% bovine serum albumin, 0.1% Tween 20), and incubated overnight at 4 °
C with polyclonal guinea pig anti-insulin (diluted 1:400) or anti-glucagon (diluted
1:500) antibodies. The sections were then incubated for 90 min with a biotinylated
goat anti–guinea pig antibody (diluted 1:750), incubated for 30 min with a
biotin–avidin complex (Vector Lab), stained using DAB (Sigma-Aldrich), and
weakly counterstained with Mayer’s hematoxylin (Millipore) without differentia-
tion. α-cell masses and β-cell masses were calculated by measuring α-cell surface
area or β-cell surface area using ImageJ software (http://rsbweb.nih.gov/ij/);
5–6 sections per pancreas and 3 pancreata were analyzed per genotype, repre-
senting a total of >500 islets analyzed per group. α-cell mass and β-cell mass were
then calculated based on individual pancreas weight.
Pancreatic insulin and glucagon content. Pancreata were rapidly extracted,
weighed, placed in acid ethanol buffer (75% EtOH; 0.55% HCl), and minced
rapidly. After overnight incubation at 4 °C, the samples were centrifuged at 1800×g
for 20 min. Insulin and glucagon content of the supernatant was then assessed by
radioimmunoassay (Merck Millipore), using insulin and glucagon standards, and
expressed relative to initial pancreatic weight.
Pancreatic islet isolation. Before removal of the pancreas, a solution of Liberase
TL 0.1 mg/mL (Roche) in quenching buffer (Hank’s buffer + 25 mM HEPES) was
injected into the pancreatic duct (2 mL/mouse). The pancreas was incubated at 37 °
C for 14 min, after which the digestion was stopped by adding cold quenching
buffer supplemented with 0.2% BSA, followed by 10 seconds of vigorous shaking,
and 2 min centrifugation at 1200×g. The pellet was then washed twice, resuspended
in 20 mL of cold RPMI (containing 11.1 mM glucose, 10% FBS, 1mM L-glutamine,
and 1% Pen/strep), and ﬁltered through a 400-μm diameter wire mesh to remove
the undigested pancreas. The solution was then ﬁltered through an inverted 100-
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μm wire mesh cell strainer, and the remaining islets were released by ﬂipping the
cell strainer in a 10 cm Petri dish containing RPMI. The islets were allowed to
recover at least 16 h before any experimental procedure.
Hormone release measurements. Measurements of insulin and glucagon secre-
tion were performed using the static incubations of islets isolated from 18-week-old
mice. The islets were pre-incubated for 30 min at 37 °C in Krebs-Ringer bicarbo-
nate buffer (KRB), pH 7.4, supplemented with 10 mM Hepes, 0.1% bovine serum
albumin, and 1 mM glucose. Each incubation vial was gassed with 95% O2 and 5%
CO2 to obtain constant pH and oxygenation. After pre-incubation the buffer was
changed to a medium containing the different conditions to be tested (1, 6, 20 mM
glucose, and 1 mM glucose + 200 µM tolbutamide). Twelve islets per milliliter
medium were incubated for 60 min. All incubations were performed at 37 °C in a
metabolic shaker (30 cycles per minute). Immediately after incubation, the aliquots
of the medium were removed for an in-house assay of insulin and glucagon28.
Measurements of insulin secretion were also performed on islets isolated from
36-week-old mice. Batches of 10 islets/milliliter were pre-incubated for 2 h at 37 °C
in KRB supplemented with 2.8 mM glucose. Insulin secretion was assessed in the
supernatant after 60 min incubation in the presence of 2.8, 10, or 20 mM glucose.
At the end of each static incubation, the islets were collected and lysed in acid
ethanol to assess insulin and glucagon content.
ATP imaging. Intact islets isolated from randomly chosen Ctrl and αGckKO-
Rosa26tdtomato mice were infected with the adenovirus encoding the ATP/ADP
sensor Perceval16 at ~106 PFU/islet. Imaging experiments were performed on a
Zeiss 510 META upright confocal microscope, using a 40 × (n.a. 0.8) objective. The
islets were perfused with extracellular solution containing (in mM): 140 NaCl, 3.6
KCl, 0.5 MgSO4, 1.3 CaCl2, 0.5 NaH2PO4, 5 NaHCO3, and 5 HEPES (pH 7.4 with
NaOH). Glucose, methyl-succinate, and FCCP have been added as indicated in
Fig. 1i and Supplementary Figs. 2, 3. Excitation/emission wavelengths were 490/
535 nm. Images were acquired at a frequency of 0.05–0.1 Hz. Imaging data were
background-subtracted, analyzed, and presented as the increase in F/F0 using
ImageJ and Igor Pro software (Wavemetrics).
Electrophysiology. All electrophysiological measurements were carried out using
an EPC-10 ampliﬁer (Heka Elektronik, Lambrecht/Pfalz, Germany) and Pulse
(version 8.80) software. Pancreatic islets were cultured overnight and transferred
into a recording chamber mounted in an upright microscope (Nikon Eclipse
E600FN, Japan), where islets were perfused with physiological saline heated by an
inline heater (chamber temperature was kept at 32–34 °C). Electrical activity,
transmembrane currents, and cell capacitance were recorded from randomly
chosen cells on the peripheral of the islets. α-cells were identiﬁed by the expression
of ﬂuorescent protein tdtomato (see Mouse Validation). α-cells were identiﬁed by
their electrical activity in response to glucose and lack of tdtomato ﬂuorescence.
Electrical activity and KATP conductance were recorded using perforated patch-
clamping technique. Perforating reagent gramicidin (0.4 mg/L) was added into
intracellular solution containing (in mM): 76 K2SO4, 10 KCl, 1 MgCl2, and 5
HEPES (pH 7.35 with KOH). Extracellular solution contains (in mM): 140 NaCl,
3.6 KCl, 0.5 MgSO4, 1.5 CaCl2, 0.5 NaH2PO4, 5 NaHCO3, and 10 HEPES (pH 7.4
with NaOH). Tolbutamide and/or D-glucose were added at concentrations as
indicated. After the experiments, the membrane potential recordings were exported
as ASCII ﬁles and converted to ABF ﬁles (axon binary ﬁle) using ABF utility
software (version 2.1.57, Synaptosoft Inc, NJ, USA). The resultant ABF ﬁles were
then imported into Clampﬁt software (version 9.2.0.11, Molecular Devices, CA,
USA) for analysis. Action potentials were detected and parameters (peak potential,
antipeak potential, and ﬁring frequency) were extracted using the ‘template search’
function of Clampﬁt.
Depolarization-triggered cell exocytosis was monitored as increase in
membrane capacitance. This was detected by the Lindau–Neher technique using
‘Sine + DC’ feature of the lock-in module of the Pulse software. The sine wave used
was 20 mV of amplitude and 1.25 kHz of frequency. The intracellular solution used
for capacitance measurement contains (in mM): 125 Cs-glutamate, 10 CsCl, 10
NaCl, 1 MgCl2, 5 HEPES, 0.05 EGTA, and 3 ATP (pH 7.2 with CsOH). The
extracellular solution contains (in mM): 118 NaCl, 5.6 KCl, 1.2 MgCl2, 2.6 CaCl2, 5
HEPES, 20 tetraethylammonium Cl (TEA-Cl), and 1 D-glucose (pH 7.4 with
NaOH).
Recording electrodes were pulled from borosilicate glass (Harvard Apparatus,
MA, USA) and had resistance of ~7MΩ when ﬁlled with intracellular solutions.
Glucose and pyruvate tolerance tests. The animals were fasted for 15 h, then
independently housed, and i.p. injected with a bolus of glucose (2 g/kg b.w.). For
pyruvate tolerance test, the mice in a random-fed state (within the ﬁrst 60 min of
light phase) received an i.p. injection of sodium pyruvate (2 g/kg b.w., Sigma
Aldrich). Blood glucose was monitored for 120 min using a glucometer (Breeze2,
Bayer) by tail vein sampling.
In vivo biochemical measurements. Plasma glucagon levels were quantitated by
radioimmunoassay (Merck Millipore) and by ELISA (Mercodia). Plasma insulin
levels were assessed by ultra-sensitive ELISA (Mercodia).
Western blotting analysis. A portion of mouse liver were homogenized in ice-
cold homogeneisation buffer (in mM: 300 sucrose, 10 HEPES pH 7.9, 10 KCl, 1.5
MgCl2, 0.1 EGTA, and 0.5 PMSF), supplemented with 1 mM sodium orthovana-
date, protease, and phosphatase inhibitor cocktail tablets (Roche). Proteins from
nuclear fractions were extracted, and the protein content was determined by
bicinchoninic acid assay (Pierce, Thermo Scientiﬁc). Equal amounts of protein (30
μg) were loaded onto 10% polyacrylamide gels and electrophoresed. Transfer to
nitrocellulose membranes was performed using the Mini Trans-Blot apparatus
from Bio-Rad. The membranes were blocked in 5% BSA (w/v) in Tris-buffered
saline with Tween-20 (TBST) (in mM: 15 Tris-HCl, 137 NaCl, 0.1% Tween-20, pH
7.6) at room temperature (RT), then incubated with anti-CREB (Cell Signaling
Technology) and anti-phospho-CREB (Ser-133) (Cell Signaling Technology)
antibodies (diluted 1:1000) in 5% BSA/TBST overnight at 4 °C. After TBST 3 × 5
min washes, the membranes were incubated for 1 h at RT with secondary anti-
rabbit HRP-conjugated antibody (GE Healthcare) diluted 1:8000 in 5% BSA/TBST,
followed by further washes. Bands corresponding to the speciﬁc proteins were
visualized using enhanced chemiluminescence reagent (Advansta). Digital images
were acquired with Fusion FX7 system (Vilber Lourmat) and Bio-1D software
(Vilber Lourmat) for quantiﬁcation and normalization. The same membranes were
reprobed with anti-β-actin antibodies to conﬁrm the equal loading of proteins for
each sample.
Liver RNA extraction and quantitative PCR analysis. Total RNA was prepared
from livers using peqGOLD TriFast according to the manufacturer’s instructions
(PeqLab). First-strand cDNA was synthesized from 1 μg of total RNA using ran-
dom primers (Promega) and M-MLV reverse transcriptase (Promega). Real-time
PCR was performed using Power SYBR Green Master Mix (Applied Biosystems).
All reactions were normalized to β-actin levels. Speciﬁc mouse primers for each
gene are listed in Supplementary Table 1.
Radioactive 2-deoxy-glucose (2-DG) uptake assay. The animals were processed
in the morning in the random-fed state. The mice received a bolus of 14C-2-deoxy-
D-glucose (Perkin-Elmer; dil. 10uCi in 100 ul saline) by retro-orbital injection
under anesthesia with isoﬂurane using an anesthetic mask on a heating pad. The
anesthesia was maintained for 2 min after the injection. The mice were then placed
in cages without water or food. Blood glucose was measured (Breeze2, Bayer) and
blood samples (30 ul) were collected from the tail tip at 0, 5, 15, 25, 35, and 45 min
post-injection. After the last blood sampling, the mice were killed by cervical
dislocation under isoﬂurane anesthesia. Tissues were immediately dissected and
frozen for further assessment of 14C-2-deoxy-D-glucose-6-phosphate (2-DG-6-P)
content. The Plasma radioactivity was determined at each time point by liquid
scintillation counting, in order to calculate the area under the curve of the plasma
tracer decay. For the determination of tissue 2-DG-6-P content, the tissue samples
were homogenized, and the supernatants were passed through ion-exchange col-
umns to separate 2-DG-6-P from 2-DG. Tissue 2DG uptake was calculated by
normalizing the tissue 2DG-6P content (as disintegrations per minute) to the tissue
weight and to the AUC of the plasma tracer decay.
Data representation and statistics. All collected data were included without data
exclusion. Statistical analysis was performed using GraphPad Prism 5.0c either by
Student’s t-test, One-way, and Two-way ANOVA followed by Bonferroni post hoc
test. The data distribution was assumed to be normal. Data are expressed as mean
± SEM. p-values less than 0.05 were considered signiﬁcant. Other statistical
methods were mentioned and indicated where they were used. No statistical
methods were used to pre-determine sample sizes, but sample sizes are similar to
those used in our previous studies.
Data availability. The data that support the ﬁndings of this study are available
from the corresponding author upon reasonable request.
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